Introduction
Bundibugyo virus disease (BVD) remains a high-consequence threat in Eastern and Central Africa, where cross-border mobility, nonspecific early symptoms, and delayed recognition can obscure transmission. In a new case report published in Nature Medicine, researchers describe Uganda’s 2026 BVD index case: a male patient who traveled from the Democratic Republic of the Congo (DRC) to Uganda and was admitted to a private hospital in Kampala on 11 May 2026 after more than two weeks of vomiting and diarrhea, with epigastric pain, weakness, and hiccups. The patient deteriorated rapidly, developing acute kidney injury, pulmonary edema, hepatic dysfunction, hypoxemia, delirium, atrial flutter, possible disseminated intravascular coagulation, and multiorgan failure, and died on 14 May. A posthumous EDTA whole-blood specimen tested at the Central Emergency Response and Surveillance Laboratory was positive for orthoebolavirus RNA and confirmed as Bundibugyo virus (BDBV) by RT-qPCR. Sequencing achieved 99% genome coverage at ≥100× depth. The 2026 BDBV genome formed a distinct lineage approximately equidistant from the 2007–2008 Butalya and 2012 Isiro variants, differing by 216–227 nucleotides (~1.2% sequence divergence).
Clinical Presentation and Rapid Deterioration
The index case presented with symptoms typical of viral hemorrhagic fevers, including prolonged vomiting and diarrhea, epigastric pain, weakness, and hiccups. However, the nonspecific nature of these symptoms initially delayed recognition of BVD. Within days of admission, the patient developed severe complications: acute kidney injury, pulmonary edema, hepatic dysfunction, hypoxemia, delirium, atrial flutter, and possible disseminated intravascular coagulation, culminating in multiorgan failure and death. This rapid clinical decline underscores the high virulence of BDBV and the challenges in managing such cases without early diagnosis. The case highlights the critical need for healthcare providers in endemic regions to maintain a high index of suspicion for viral hemorrhagic fevers, especially in patients with travel history from areas with known outbreaks.
Genomic Characterization and Evolutionary Insights
Genomic sequencing of the 2026 BDBV strain achieved 99% coverage at high depth, enabling detailed phylogenetic analysis. The 2026 genome forms a distinct lineage that is approximately equidistant from the 2007–2008 Butalya and 2012 Isiro variants, differing by 216–227 nucleotides, representing about 1.2% sequence divergence. This suggests ongoing evolution of BDBV in the region, with potential implications for diagnostic accuracy, vaccine efficacy, and therapeutic development. The emergence of a new lineage emphasizes the importance of continuous genomic surveillance to monitor viral changes and inform public health responses.
Surveillance and Diagnostic Challenges
The case was detected through fatality surveillance and private-sector engagement, demonstrating the value of expanding surveillance beyond traditional public health facilities. The Central Emergency Response and Surveillance Laboratory played a crucial role in confirming the diagnosis through RT-qPCR and genomic sequencing. National specimen referral systems enabled timely testing, highlighting the need for robust laboratory networks in resource-limited settings. However, the delayed recognition and rapid death of the patient indicate gaps in early detection and response. Strengthening surveillance at points of entry, improving clinical awareness, and enhancing diagnostic capacity are essential to prevent further spread.
Public Health Implications
Bundibugyo virus is a filovirus closely related to Ebola virus, and outbreaks have historically occurred in Uganda and DRC. The 2026 index case underscores the persistent threat of BVD in a region characterized by high cross-border mobility. The nonspecific early symptoms and potential for delayed recognition can obscure transmission chains, leading to undetected spread. Public health authorities must prioritize integrated disease surveillance, rapid diagnostic deployment, and community engagement to improve outbreak detection and response. The genomic data also provide a baseline for monitoring viral evolution and assessing the effectiveness of existing countermeasures.
Conclusion
The 2026 Bundibugyo virus index case in Uganda highlights the lethal potential of BVD and the importance of robust surveillance systems. The rapid clinical deterioration and distinct genomic lineage of the virus underscore the need for continued investment in diagnostic infrastructure, genomic surveillance, and cross-border collaboration. By learning from this case, public health agencies can better prepare for future outbreaks and mitigate the impact of this high-consequence pathogen.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com
